Literature DB >> 12001044

A comprehensive study of Candida-specific antibodies in the saliva of human immunodeficiency virus-positive individuals with oropharyngeal candidiasis.

Karen L Wozniak1, Janet E Leigh, Shannon Hager, Rolf K Swoboda, Paul L Fidel.   

Abstract

Oropharyngeal candidiasis (OPC) is a common oral opportunistic infection among human immunodeficiency virus (HIV)-positive individuals. Although most cases of OPC correlate with reduced systemic levels of CD4(+) T cells, the role of humoral immunity in protection against mucosal candidiasis, including OPC, remains questionable. In the present study, a comprehensive analysis of saliva from 33 HIV-negative and 68 HIV-positive individuals, stratified by OPC status and peripheral CD4(+) cell count, was conducted to measure levels of total and Candida-specific immunoglobulin A(IgA) and IgG antibodies, including subclasses and secretory IgA. Despite changes in total immunoglobulin levels, when levels of Candida-specific antibodies were normalized to total protein or total immunoglobulin of the corresponding isotype, no distinct differences in IgG (including subclasses), IgA (including subclasses), or secretory IgA levels were seen, regardless of HIV status, OPC status, or CD4(+) cell count. These data suggest that when a complete repertoire of antibodies is evaluated, with appropriate normalization of data, there is no evidence of appreciable changes in levels of Candida-specific antibodies in saliva that would account for the prevalence of OPC among HIV-positive individuals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001044     DOI: 10.1086/339886

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis.

Authors:  P L Fidel
Journal:  Adv Dent Res       Date:  2011-04

2.  Pseudomembranous Type of Oral Candidiasis is Associated with Decreased Salivary Flow Rate and Secretory Immunoglobulin A Levels.

Authors:  Bela Mahajan; Neeta Bagul; Rajiv Desai; Mamatha Reddy; Amit Mahajan; Ashwini Shete; Arun Risbud; Arati Mane
Journal:  Mycopathologia       Date:  2015-02-15       Impact factor: 2.574

3.  Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis.

Authors:  Theo S Plantinga; Omar J M Hamza; Janet A Willment; Bart Ferwerda; Nicole M D van de Geer; Paul E Verweij; Mecky I N Matee; Kathy Banahan; Luke A J O'neill; Bart-Jan Kullberg; Gordon D Brown; André J A M van der Ven; Mihai G Netea
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

4.  Characterization of CD8+ T cells and microenvironment in oral lesions of human immunodeficiency virus-infected persons with oropharyngeal candidiasis.

Authors:  Kelly M McNulty; Jananya Plianrungsi; Janet E Leigh; Donald Mercante; Paul L Fidel
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 5.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Candida-specific antibodies during experimental vaginal candidiasis in mice.

Authors:  Karen L Wozniak; Floyd L Wormley; Paul L Fidel
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

7.  Associations among the use of highly active antiretroviral therapy, oral candidiasis, oral Candida species and salivary immunoglobulin A in HIV-infected children.

Authors:  Luciana Pomarico; Daniella Ferraz Cerqueira; Rosangela Maria de Araujo Soares; Ivete Pomarico Ribeiro de Souza; Gloria Fernanda Barbosa de Araujo Castro; Sigmund Socransky; Anne Haffajee; Ricardo Palmier Teles
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-08

8.  Immunohistochemical evaluation of T cells in oral lesions from human immunodeficiency virus-positive persons with oropharyngeal candidiasis.

Authors:  Tammy A Myers; Janet E Leigh; Alfredo R Arribas; Shannon Hager; Rebecca Clark; Elizabeth Lilly; Paul L Fidel
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

9.  Modulation of in vitro fungicidal activity of human lactoferrin against Candida albicans by extracellular cation concentration and target cell metabolic activity.

Authors:  Mónica Viejo-Díaz; María T Andrés; José F Fierro
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons.

Authors:  Amit Chattopadhyay; Laurie R Gray; Lauren L Patton; Daniel J Caplan; Gary D Slade; Hsaio-Chuan Tien; Diane C Shugars
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.